title: Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
abstract: OBJECTIVE
  To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome.
  
  
  METHODS
  We identified all HIV-1-infected women who received NVP as part of a triple antiretroviral regimen during pregnancy between January 1997 and September 1999. Laboratory results, clinical events, side-effects and pregnancy outcome were abstracted using a standardized proforma from the medical records.
  
  
  RESULTS
  Forty-six women were identified, 85% of whom were black African. At initiation of NVP, the median age was 29 years and the median baseline CD4 cell count and viral load were 242 cells/microL and 4.15 log10 copies/mL, respectively. Thirty-two out of 36 women who had a plasma sample obtained at, or just prior to, delivery had an undetectable viral load (< 50 to < 400 copies/mL). Adverse events that were definitely attributed to NVP included a generalized rash (n = 2) and hepatitis (n = 2). Obstetric complications occurred in nine women (19.5%), which was not statistically different (P = 0.36) from that found in a historical (1990-96) control group 7/51 (14%). The rate of preterm delivery (13%) was similar to that previously reported in HIV-1 infected pregnant women (18%).
  
  
  CONCLUSIONS
  NVP (as part of highly active antiretroviral therapy) reduced plasma viraemia to below the limit of detection in 89% of women. It was generally well tolerated and clinical and laboratory adverse events were infrequent. There was no evidence of an increase in obstetric complications including preterm delivery during the second and third trimesters of pregnancy.
authors.affiliation: King's College Hospital, St Thomas' Hospital, St George's Hospital and St Mary's Hospital, London, UK. Sedwards@cichs-tr.nthames.nhs.uk
authors.forename: S G
authors.initials: SG
authors.lastname: Edwards
authors.forename: N
authors.initials: N
authors.lastname: Larbalestier
authors.forename: P
authors.initials: P
authors.lastname: Hay
authors.forename: A
authors.initials: A
authors.lastname: de Ruiter
authors.forename: J
authors.initials: J
authors.lastname: Welch
authors.forename: G P
authors.initials: GP
authors.lastname: Taylor
authors.forename: P
authors.initials: P
authors.lastname: Easterbrook
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011256:Pregnancy Outcome; D019562:Viral Load; D014766:Viremia
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine